REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study

Summary

The worldwide COVID-19 pandemic has led to a dramatic increase in the number of patients hospitalized in intensive care units for an acute respiratory failure in all countries. This situation has quickly led to massive shortage in masks, mechanical ventilation machines and common medications such as hypnotics. All countries over the world are currently experiencing a major shortage in basic hypnotic medications (propofol, midazolam) in the intensive care as well as in the operating theatre. The Principal Investigator proposes to perform a pilot study assessing the benefit-risk ratio of Remimazolam (a novel benzodiazepine with a short half-life) in the critical care units of Nantes University Hospital during the COVID-19 pandemic.

Timeline

Start

2020-11-30

Primary completion

2020-12-02

Completion

2021-10-22

Publications

• Grillot N, Vourc'h M, Hourmant Y, Bouras M, Rozec B, Rouhani A, Stoehr T, Jobert A, Roquilly A, Cinotti R. A phase 2 open-label pilot study of Remimazolam for sedation in critically ill patients. Anaesth Crit Care Pain Med. 2025 May;44(3):101510. doi: 10.1016/j.accpm.2025.101510. Epub 2025 Mar 31.

Drugs

Indications